{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:39:49Z","timestamp":1790840389048,"version":"4.1.0"},"reference-count":101,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T00:00:00Z","timestamp":1620518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Leukaemia Lymphoma NI","award":["R2536CNR, R2460CNR"],"award-info":[{"award-number":["R2536CNR, R2460CNR"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Myeloid malignancy is a broad term encapsulating myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). Initial studies into genomic profiles of these diseases have shown 2000 somatic mutations prevalent across the spectrum of myeloid blood disorders. Epigenetic mutations are emerging as critical components of disease progression, with mutations in genes controlling chromatin regulation and methylation\/acetylation status. Genes such as DNA methyltransferase 3A (DNMT3A), ten eleven translocation methylcytosine dioxygenase 2 (TET2), additional sex combs-like 1 (ASXL1), enhancer of zeste homolog 2 (EZH2) and isocitrate dehydrogenase 1\/2 (IDH1\/2) show functional impact in disease pathogenesis. In this review we discuss how current knowledge relating to disease progression, mutational profile and therapeutic potential is progressing and increasing understanding of myeloid malignancies.<\/jats:p>","DOI":"10.3390\/ijms22095013","type":"journal-article","created":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T21:32:46Z","timestamp":1620595966000},"page":"5013","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["The Impact of Epigenetic Modifications in Myeloid Malignancies"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7227-8728","authenticated-orcid":false,"given":"Deirdra","family":"Venney","sequence":"first","affiliation":[{"name":"Patrick G Johnston Center for Cancer Research, Queens University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2932-954X","authenticated-orcid":false,"given":"Adone","family":"Mohd-Sarip","sequence":"additional","affiliation":[{"name":"Patrick G Johnston Center for Cancer Research, Queens University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken I","family":"Mills","sequence":"additional","affiliation":[{"name":"Patrick G Johnston Center for Cancer Research, Queens University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrc3343","article-title":"The role of mutations in epigenetic regulators in myeloid malignancies","volume":"12","author":"Shih","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.3324\/haematol.2013.092007","article-title":"Epigenetics in the hematologic malignancies [Internet]","volume":"997","author":"Fong","year":"2014","journal-title":"Haematologica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1182\/blood-2013-01-451781","article-title":"Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia","volume":"121","author":"Levine","year":"2013","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/blood-2005-01-0178","article-title":"Drug therapy for acute myeloid leukemia","volume":"106","author":"Tallman","year":"2005","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.ctrv.2007.07.009","article-title":"Targets of epigenetic therapy\u2014Gene reactivation as a novel approach in MDS treatment","volume":"33","author":"Claus","year":"2007","journal-title":"Cancer Treat. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2013). Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med., 368, 2059\u20132074.","DOI":"10.1056\/NEJMoa1301689"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/imr.12246","article-title":"The role of mutations in epigenetic regulators in myeloid malignancies","volume":"263","author":"Woods","year":"2015","journal-title":"Immunol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrc.2017.40","article-title":"Turning the tide in myelodysplastic\/myeloproliferative neoplasms","volume":"17","author":"Deininger","year":"2017","journal-title":"Nat. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2141.1989.tb00221.x","article-title":"Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: A report on 283 cases","volume":"73","author":"Fenaux","year":"1989","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1046\/j.1365-2141.2001.02511.x","article-title":"Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: A study of 90 patients","volume":"112","author":"Schoch","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_14","first-page":"408","article-title":"A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group","volume":"89","author":"Haferlach","year":"2004","journal-title":"Hematology"},{"key":"ref_15","first-page":"329","article-title":"Acute myeloid leukemia\u2014genetic alterations and their clinical prognosis","volume":"11","year":"2017","journal-title":"Int. J. Hematol. Stem Cell Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/asheducation-2016.1.348","article-title":"Mutations in AML: Prognostic and therapeutic implications","volume":"2016","author":"Cortes","year":"2016","journal-title":"Hematology"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Yang, X., Wong, M.P.M., and Ng, R.K. (2019). Aberrant DNA methylation in acute myeloid leukemia and its clinical implications. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184576"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3389\/fgene.2019.00346","article-title":"Identification of DNA-Methylated CpG Islands Associated With Gene Silencing in the Adult Body Tissues of the Ogye Chicken Using RNA-Seq and Reduced Representation Bisulfite Sequencing","volume":"10","author":"Lim","year":"2019","journal-title":"Front. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3AMutations in Acute Myeloid Leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.cell.2017.01.021","article-title":"CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression","volume":"168","author":"Spencer","year":"2017","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"11453","DOI":"10.1038\/ncomms11453","article-title":"DNMT3B isoforms without catalytic activity stimulate gene body methylation as accessory proteins in somatic cells","volume":"7","author":"Duymich","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1097\/MD.0000000000003519","article-title":"DNMT3A r882 mutations predict a poor prognosis in AML a meta-analysis from 4474 patients","volume":"95","author":"Yuan","year":"2016","journal-title":"Medicine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"10924","DOI":"10.1038\/ncomms10924","article-title":"DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation","volume":"7","author":"Koya","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"a030320","DOI":"10.1101\/cshperspect.a030320","article-title":"DNMT3A in Leukemia","volume":"7","author":"Brunetti","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/nm.4210","article-title":"DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling","volume":"22","author":"Guryanova","year":"2016","journal-title":"Nat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-014-0074-4","article-title":"Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations","volume":"7","author":"Loghavi","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.2011.35.4894","article-title":"Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia","volume":"29","author":"Thol","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/ng1089","article-title":"Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals","volume":"33","author":"Jaenisch","year":"2003","journal-title":"Nat. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nbt.3605","article-title":"Quantitative comparison of DNA methylation assays for biomarker development and clinical applications","volume":"34","author":"Bock","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2217\/epi.15.114","article-title":"Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences","volume":"8","author":"Moran","year":"2016","journal-title":"Epigenomics"},{"key":"ref_31","first-page":"1","article-title":"Characterization of functional methylomes by next-generation capture sequencing identifies novel disease-associated variants","volume":"6","author":"Allum","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","article-title":"DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia","volume":"17","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood-2019-130047","article-title":"DNA Methylation Profiling of AML Reveals Epigenetic Subgroups with Distinct Clinical Outcome","volume":"134","author":"Vosberg","year":"2019","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation inTET2in Myeloid Cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1200\/JCO.2010.32.7742","article-title":"TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study","volume":"29","author":"Metzeler","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_37","first-page":"1129","article-title":"Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification","volume":"466","author":"Ito","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1182\/blood-2010-12-325241","article-title":"Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies","volume":"118","author":"Li","year":"2011","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1182\/blood-2009-02-205690","article-title":"Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic\/myeloproliferative neoplasms","volume":"113","author":"Jankowska","year":"2009","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","article-title":"Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation","volume":"20","author":"Reavie","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/leu.2011.326","article-title":"Landscape of TET2 mutations in acute myeloid leukemia","volume":"26","author":"Weissmann","year":"2012","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.cell.2011.11.054","article-title":"Mbd3\/NURD Complex Regulates Expression of 5-Hydroxymethylcytosine Marked Genes in Embryonic Stem Cells","volume":"147","author":"Yildirim","year":"2011","journal-title":"Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting \u03b1-Ketoglutarate to 2-Hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An Integrated Genomic Analysis of Human Glioblastoma Multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","article-title":"IDH1andIDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study","volume":"28","author":"Marcucci","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Kattih, B., Shirvani, A., Klement, P., Garrido, A.M., Gabdoulline, R., Liebich, A., Brandes, M., Chaturvedi, A., Seeger, T., and Thol, F. (2020). IDH1\/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction\u2014a retrospective propensity score analysis. Leukemia, 1\u201316.","DOI":"10.1038\/s41375-020-01043-x"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.14740\/jocmr2405w","article-title":"The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis","volume":"8","author":"Hindilerden","year":"2016","journal-title":"J. Clin. Med. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/leu.2014.124","article-title":"DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: Associations with prognosis and potential treatment strategies","volume":"28","author":"Im","year":"2014","journal-title":"Leukemia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3324\/haematol.2018.191148","article-title":"Persistent IDH1\/2 mutations in remission can predict relapse in patients with acute myeloid leukemia","volume":"104","author":"Ok","year":"2019","journal-title":"Haematologica"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2007.05.009","article-title":"High-Resolution Profiling of Histone Methylations in the Human Genome","volume":"129","author":"Barski","year":"2007","journal-title":"Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/15592294.2018.1503491","article-title":"Recognition of cancer mutations in histone H3K36 by epigenetic writers and readers","volume":"13","author":"Klein","year":"2018","journal-title":"Epigenetics"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrc2253","article-title":"MLL translocations, histone modifications and leukaemia stem-cell development [Internet]","volume":"7","author":"Krivtsov","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/sj.leu.2402708","article-title":"Acute myeloid leukemia with MLL rearrangements: Clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells","volume":"17","author":"Munoz","year":"2003","journal-title":"Leukemia"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Schafer, E.S., Margolin, J., Poplack, D.G., and Rabin, K.R. (2015). Molecular Genetics of Acute Lymphoblastic Leukemia. The Molecular Basis of Cancer: Fourth Edition, Elsevier BV.","DOI":"10.1016\/B978-1-4557-4066-6.00026-3"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fped.2017.00004","article-title":"MLL-rearranged leukemias- An update on science and clinical approaches","volume":"5","author":"Winters","year":"2017","journal-title":"Front. Pediatr."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"10610","DOI":"10.1073\/pnas.91.22.10610","article-title":"11q23 translocations split the \"AT-hook\" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene","volume":"91","author":"Harden","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Gruber, T.A., and Rubnitz, J.E. (2018). Acute Myeloid Leukemia in Children, Elsevier BV.","DOI":"10.1016\/B978-0-323-35762-3.00062-7"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/leu.2017.213","article-title":"The MLL recombinome of acute leukemias in 2017","volume":"32","author":"Meyer","year":"2018","journal-title":"Leukemia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/asheducation-2011.1.354","article-title":"Targeting Epigenetic Programs in MLL-Rearranged Leukemias","volume":"2011","author":"Bernt","year":"2011","journal-title":"Hematology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1076997","article-title":"Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing","volume":"298","author":"Cao","year":"2002","journal-title":"Science"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.gendis.2019.05.001","article-title":"Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasms","volume":"6","author":"Zhang","year":"2019","journal-title":"Genes Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2018-99-114421","article-title":"EZH2 Mutations and Impact on Clinical Outcome Analyzed in 1604 Patients with Acute Myeloid Leukemia","volume":"132","author":"Stasik","year":"2018","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1101\/gad.1200204","article-title":"Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27","volume":"18","author":"Kirmizis","year":"2004","journal-title":"Genes Dev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1084\/jem.20181276","article-title":"Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML","volume":"216","author":"Basheer","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","article-title":"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation","volume":"117","author":"Yap","year":"2011","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.molcel.2008.10.016","article-title":"EZH1 Mediates Methylation on Histone H3 Lysine 27 and Complements EZH2 in Maintaining Stem Cell Identity and Executing Pluripotency","volume":"32","author":"Shen","year":"2008","journal-title":"Mol. Cell"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Wang, X., Dai, H., Wang, Q., Wang, Q., Xu, Y., Wang, Y., Sun, A., Ruan, J., Chen, S., and Wu, D. (2013). EZH2 Mutations Are Related to Low Blast Percentage in Bone Marrow and -7\/del(7q) in De Novo Acute Myeloid Leukemia. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061341"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1756-8722-5-12","article-title":"Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases","volume":"5","author":"Brecqueville","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Chen, S.-L., Qin, Z.-Y., Hu, F., Wang, Y., Dai, Y.-J., and Liang, Y. (2019). The Role of the HOXA Gene Family in Acute Myeloid Leukemia. Genes, 10.","DOI":"10.3390\/genes10080621"},{"key":"ref_71","first-page":"388","article-title":"Acquired mutations in ASXL1 in acute myeloid leukemia: Prevalence and prognostic value","volume":"97","author":"Pratcorona","year":"2011","journal-title":"Hematology"},{"key":"ref_72","first-page":"324","article-title":"ASXL1 mutations in younger adult patients with acute myeloid leukemia: A study by the German-Austrian Acute Myeloid Leukemia Study Group","volume":"100","author":"Paschka","year":"2015","journal-title":"Hematology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0789-3","article-title":"RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia","volume":"12","author":"Bera","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood-2009-07-233858","article-title":"Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML","volume":"115","author":"Paul","year":"2010","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","article-title":"Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia","volume":"28","author":"Cashen","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"ref_77","first-page":"23","article-title":"HOX genes: Seductive science, mysterious mechanisms","volume":"75","author":"Lappin","year":"2006","journal-title":"Ulst. Med. J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2015-11-684225","article-title":"DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia","volume":"128","author":"Rau","year":"2016","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccell.2015.02.016","article-title":"Pharmacologic inhibition of the menin-MLL interaction blocks progression of MLL leukemia invivo","volume":"27","author":"Borkin","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/5047","article-title":"Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer","volume":"21","author":"Cameron","year":"1999","journal-title":"Nat. Genet."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/bloodadvances.2018027409","article-title":"Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: Results of a phase 2 study","volume":"3","author":"Abaza","year":"2019","journal-title":"Blood Adv."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"key":"ref_83","first-page":"1","article-title":"BRCA2-associated therapy-related acute myeloid leukemia","volume":"32","author":"Rashidi","year":"2014","journal-title":"Med. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3389\/fonc.2019.00210","article-title":"TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair","volume":"9","author":"Feng","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0242-4","article-title":"Clinical remission following ascorbate treatment in a case of acute myeloid leukemia with mutations in TET2 and WT1","volume":"9","author":"Das","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.cell.2017.07.032","article-title":"Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression","volume":"170","author":"Cimmino","year":"2017","journal-title":"Cell"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fcell.2019.00128","article-title":"Reprogramming the Epigenome with Vitamin C","volume":"7","author":"Ahearn","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3109\/10428194.2013.855309","article-title":"Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents","volume":"55","author":"DiNardo","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1231677","article-title":"(R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible","volume":"339","author":"Losman","year":"2013","journal-title":"Science"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1182\/blood-2013-03-491571","article-title":"Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML","volume":"122","author":"Chaturvedi","year":"2013","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.exphem.2013.12.001","article-title":"Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations","volume":"42","author":"Emadi","year":"2014","journal-title":"Exp. Hematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0814-6","article-title":"EZH2 abnormalities in lymphoid malignancies: Underlying mechanisms and therapeutic implications","volume":"12","author":"Li","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood-2014-06-581082","article-title":"Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia","volume":"125","author":"Xu","year":"2015","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.csbj.2019.01.006","article-title":"Bivalent Ligands for Protein Degradation in Drug Discovery","volume":"17","author":"Scheepstra","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1182\/blood.V126.23.3786.3786","article-title":"In Acute Myeloid Leukemia (AML), Targeting the Histone Methyltransferase EZH2 Promotes Differentiation, Impairs Clonogenic Survival and Augments the Anti-Leukemic Effects of the Retinoid, All-Trans-Retinoic Acid (ATRA)","volume":"126","author":"Swords","year":"2015","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood-2009-03-213496","article-title":"Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells","volume":"114","author":"Fiskus","year":"2009","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/leu.2016.126","article-title":"RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features","volume":"30","author":"Gaidzik","year":"2016","journal-title":"Leukemia"},{"key":"ref_99","first-page":"3651","article-title":"Co-occurrence of RUNX1 and ASXL1 mutations underlie poor response and outcome for MDS patients treated with HMAs","volume":"11","author":"Wu","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/leu.2016.163","article-title":"Subtype-specific patterns of molecular mutations in acute myeloid leukemia","volume":"31","author":"Rose","year":"2017","journal-title":"Leukemia"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/9\/5013\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:58:27Z","timestamp":1760162307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/9\/5013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,9]]},"references-count":101,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["ijms22095013"],"URL":"https:\/\/doi.org\/10.3390\/ijms22095013","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,9]]}}}